Evidence map›Paper›PMID 42086533›Full record

ArticleCell death & disease2026

Proteasomal-dependent CHK1 degradation leads to DNA damage accumulation in ALS cellular model systems.

Stefania Modafferi, Valentina Silenzi, Anna Garbelli, Gloria Lazoi, Eveljn Scarian, Sara D'Uva, Tiziana Santini, Adelaide Riccardi, Mauro Cozzolino, Orietta Pansarasa and 4 more

Abstract read
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Stefania ModafferiInstitute of Molecular Genetics, National Research Council (CNR), Pavia, Italy.
Valentina SilenziDepartment of Biology and Biotechnologies "Charles Darwin", Sapienza University of Rome, Rome, Italy.
Anna GarbelliInstitute of Molecular Genetics, National Research Council (CNR), Pavia, Italy.
Gloria LazoiInstitute of Molecular Genetics, National Research Council (CNR), Pavia, Italy.
Eveljn ScarianCellular Models and Neuroepigenetics Section, IRCCS Mondino Foundation, Pavia, Italy.
Sara D'UvaDepartment of Biology and Biotechnologies "Charles Darwin", Sapienza University of Rome, Rome, Italy.
Tiziana SantiniDepartment of Biology and Biotechnologies "Charles Darwin", Sapienza University of Rome, Rome, Italy.
Adelaide RiccardiInstitute of Molecular Genetics, National Research Council (CNR), Pavia, Italy.
Mauro CozzolinoInstitute of Translational Pharmacology, CNR, Rome, Italy.ORCID http://orcid.org/0000-0003-0342-8961
Orietta PansarasaCellular Models and Neuroepigenetics Section, IRCCS Mondino Foundation, Pavia, Italy.
Nadia D'AmbrosiDepartment of Biology, University of Rome Tor Vergata, Rome, Italy.ORCID http://orcid.org/0000-0002-6646-7653
Simone SabbionedaInstitute of Molecular Genetics, National Research Council (CNR), Pavia, Italy.
Mariangela MorlandoDepartment of Biology and Biotechnologies "Charles Darwin", Sapienza University of Rome, Rome, Italy.
Sofia FranciaInstitute of Molecular Genetics, National Research Council (CNR), Pavia, Italy. sofia.francia@cnr.it.ORCID http://orcid.org/0000-0002-4578-9442

Funding

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG-2020-24316Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG2022-27833Consiglio Nazionale delle Ricerche (National Research Council) DBA.AD005.225-NUTRAGE-FOE2021Consiglio Nazionale delle Ricerche (National Research Council) FOE-2021 DBA.AD005.225Istituto Superiore di Sanità (ISS) RIPREI2023_7c8ae10d783cMinistero della Salute (Ministry of Health, Italy) Ricerca Corrente 2025 - 2027Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) 2017KSZZJWMinistero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) 2017NWEXEPMinistero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) 2020CXFL4TMinistero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) 2022JA8JY5Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) 2022R7LH5TMinistero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) DN. 1553 11.10.2022Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) PNRR-CN3 642 "National Center for Gene Therapy and Drugs based on RNA Technology"Regione Lombardia (Region of Lombardy) DSB.AD004.294Sapienza Università di Roma (Sapienza University of Rome) RG12419107CD28D5
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is characterised by the aggregation of TDP-43 and mutant FUS in the cytoplasm of affected motor neurons. Accumulation of DNA damage is emerging as a novel correlative trait of ALS. We recently showed that formation of TDP-43 and FUS cytoplasmic inclusions (CIs) lead to DNA damage accumulation through dysregulation of the DNA damage response (DDR). However, the multiple molecular mechanisms contributing to DNA damage accumulation in affected motor neurons in ALS have not been fully elucidated. In recent years, chemical inhibition of the serine/threonine kinase CHK1 was shown to lead to accumulation of DNA breaks as well as increased apoptosis, in differentiated cortical neurons. Notably, CHK1 has been involved in DNA double-strand break repair in non-dividing cells, by acting through the histone chaperone ASF1A. In this article, we show that cells bearing FUS and TDP-43 CIs show downregulation of the protein levels of CHK1 and ASF1A. We observe CHK1 protein downregulation in neuronal cell lines, as well as in patient-derived motor neurons progenitors and in the spinal cord of a FUS-ALS mouse model. Restoration of the nuclear levels of CHK1 and ASF1A via transient overexpression, is sufficient to reduce DNA damage signal accumulation and rescues DDR defects. Importantly, we show that the ubiquitin-proteasome pathway is responsible for CHK1 degradation in cells bearing FUS CI, since its inhibition restores CHK1 and ASF1A protein levels. Our study demonstrates that proteasomal-dependent CHK1 and ASF1A downregulation contributes to accumulation of DNA damage in cells affected by ALS-linked protein aggregates.

Indexed as

Amyotrophic Lateral SclerosisCheckpoint Kinase 1DNA DamageProteasome Endopeptidase ComplexAnimalsDisease Models, AnimalDNA-Binding ProteinsDNA RepairHistone ChaperonesHumansMiceMotor NeuronsProteolysisRNA-Binding Protein FUSCheckpoint Kinase 1CHEK1 protein, humanChek1 protein, mouseDNA-Binding ProteinsHistone ChaperonesProteasome Endopeptidase ComplexRNA-Binding Protein FUS

Identifiers

PMID42086533
PMCPMC13315745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.